nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketobemidone—UGT1A9—Mycophenolic acid—psoriasis	0.239	0.25	CbGbCtD
Ketobemidone—UGT1A9—Mycophenolate mofetil—psoriasis	0.134	0.14	CbGbCtD
Ketobemidone—CYP2C8—Tazarotene—psoriasis	0.0866	0.0905	CbGbCtD
Ketobemidone—CYP2B6—Cholecalciferol—psoriasis	0.0488	0.051	CbGbCtD
Ketobemidone—CYP2C8—Cholecalciferol—psoriasis	0.037	0.0386	CbGbCtD
Ketobemidone—CYP2C8—Mycophenolate mofetil—psoriasis	0.0321	0.0335	CbGbCtD
Ketobemidone—CYP2C19—Cholecalciferol—psoriasis	0.031	0.0324	CbGbCtD
Ketobemidone—CYP3A4—Calcitriol—psoriasis	0.0291	0.0304	CbGbCtD
Ketobemidone—CYP2C9—Cholecalciferol—psoriasis	0.0258	0.027	CbGbCtD
Ketobemidone—CYP2C8—Hydrocortisone—psoriasis	0.0257	0.0269	CbGbCtD
Ketobemidone—CYP2C8—Cyclosporine—psoriasis	0.0243	0.0254	CbGbCtD
Ketobemidone—CYP3A4—Methoxsalen—psoriasis	0.0226	0.0237	CbGbCtD
Ketobemidone—CYP2C19—Prednisone—psoriasis	0.0215	0.0225	CbGbCtD
Ketobemidone—CYP2B6—Dexamethasone—psoriasis	0.0211	0.0221	CbGbCtD
Ketobemidone—CYP2C19—Cyclosporine—psoriasis	0.0204	0.0213	CbGbCtD
Ketobemidone—CYP2C9—Cyclosporine—psoriasis	0.0169	0.0177	CbGbCtD
Ketobemidone—CYP2C8—Dexamethasone—psoriasis	0.016	0.0167	CbGbCtD
Ketobemidone—CYP3A4—Cholecalciferol—psoriasis	0.015	0.0157	CbGbCtD
Ketobemidone—CYP2C19—Dexamethasone—psoriasis	0.0134	0.014	CbGbCtD
Ketobemidone—CYP3A4—Mycophenolate mofetil—psoriasis	0.013	0.0136	CbGbCtD
Ketobemidone—CYP3A4—Triamcinolone—psoriasis	0.013	0.0136	CbGbCtD
Ketobemidone—CYP2C9—Dexamethasone—psoriasis	0.0112	0.0117	CbGbCtD
Ketobemidone—CYP3A4—Betamethasone—psoriasis	0.0112	0.0117	CbGbCtD
Ketobemidone—CYP3A4—Prednisolone—psoriasis	0.011	0.0115	CbGbCtD
Ketobemidone—CYP3A4—Hydrocortisone—psoriasis	0.0104	0.0109	CbGbCtD
Ketobemidone—CYP3A4—Prednisone—psoriasis	0.0104	0.0109	CbGbCtD
Ketobemidone—CYP3A4—Cyclosporine—psoriasis	0.00985	0.0103	CbGbCtD
Ketobemidone—CYP3A4—Dexamethasone—psoriasis	0.00649	0.00678	CbGbCtD
Ketobemidone—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00249	0.0571	CbGpPWpGaD
Ketobemidone—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00211	0.0484	CbGpPWpGaD
Ketobemidone—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00188	0.0432	CbGpPWpGaD
Ketobemidone—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00171	0.0394	CbGpPWpGaD
Ketobemidone—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00154	0.0354	CbGpPWpGaD
Ketobemidone—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00131	0.03	CbGpPWpGaD
Ketobemidone—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00117	0.0268	CbGpPWpGaD
Ketobemidone—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00106	0.0244	CbGpPWpGaD
Ketobemidone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000701	0.0161	CbGpPWpGaD
Ketobemidone—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00068	0.0156	CbGpPWpGaD
Ketobemidone—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00064	0.0147	CbGpPWpGaD
Ketobemidone—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000632	0.0145	CbGpPWpGaD
Ketobemidone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000542	0.0125	CbGpPWpGaD
Ketobemidone—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000535	0.0123	CbGpPWpGaD
Ketobemidone—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000519	0.0119	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	0.000504	0.0116	CbGpPWpGaD
Ketobemidone—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000502	0.0115	CbGpPWpGaD
Ketobemidone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000494	0.0113	CbGpPWpGaD
Ketobemidone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000484	0.0111	CbGpPWpGaD
Ketobemidone—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000477	0.011	CbGpPWpGaD
Ketobemidone—UGT1A9—Biological oxidations—CYP2S1—psoriasis	0.000443	0.0102	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	0.000442	0.0102	CbGpPWpGaD
Ketobemidone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000441	0.0101	CbGpPWpGaD
Ketobemidone—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000439	0.0101	CbGpPWpGaD
Ketobemidone—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000437	0.01	CbGpPWpGaD
Ketobemidone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000435	0.01	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000401	0.0092	CbGpPWpGaD
Ketobemidone—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000392	0.00901	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	0.000373	0.00858	CbGpPWpGaD
Ketobemidone—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000361	0.0083	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—REL—psoriasis	0.000361	0.00829	CbGpPWpGaD
Ketobemidone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000358	0.00822	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000351	0.00807	CbGpPWpGaD
Ketobemidone—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000327	0.0075	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	0.00031	0.00713	CbGpPWpGaD
Ketobemidone—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	0.00031	0.00712	CbGpPWpGaD
Ketobemidone—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.00031	0.00711	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—HCAR2—psoriasis	0.000305	0.00701	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000304	0.00698	CbGpPWpGaD
Ketobemidone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000303	0.00696	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000297	0.00682	CbGpPWpGaD
Ketobemidone—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000294	0.00676	CbGpPWpGaD
Ketobemidone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000291	0.00668	CbGpPWpGaD
Ketobemidone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000287	0.0066	CbGpPWpGaD
Ketobemidone—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000278	0.00639	CbGpPWpGaD
Ketobemidone—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000276	0.00633	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000272	0.00625	CbGpPWpGaD
Ketobemidone—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000272	0.00625	CbGpPWpGaD
Ketobemidone—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.000271	0.00622	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—HCAR2—psoriasis	0.000267	0.00615	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	0.000262	0.00601	CbGpPWpGaD
Ketobemidone—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000247	0.00567	CbGpPWpGaD
Ketobemidone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000236	0.00542	CbGpPWpGaD
Ketobemidone—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000233	0.00536	CbGpPWpGaD
Ketobemidone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000233	0.00535	CbGpPWpGaD
Ketobemidone—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.00023	0.00529	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	0.00023	0.00528	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	0.000229	0.00527	CbGpPWpGaD
Ketobemidone—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000227	0.00522	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—HCAR2—psoriasis	0.000226	0.00519	CbGpPWpGaD
Ketobemidone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000212	0.00488	CbGpPWpGaD
Ketobemidone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000209	0.0048	CbGpPWpGaD
Ketobemidone—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000208	0.00479	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000208	0.00478	CbGpPWpGaD
Ketobemidone—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000205	0.00472	CbGpPWpGaD
Ketobemidone—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000205	0.00471	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	0.000204	0.00469	CbGpPWpGaD
Ketobemidone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000203	0.00466	CbGpPWpGaD
Ketobemidone—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000202	0.00464	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	0.000194	0.00446	CbGpPWpGaD
Ketobemidone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.00019	0.00436	CbGpPWpGaD
Ketobemidone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000187	0.0043	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000186	0.00426	CbGpPWpGaD
Ketobemidone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000184	0.00422	CbGpPWpGaD
Ketobemidone—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000183	0.00421	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000182	0.00419	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	0.000172	0.00396	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CCL20—psoriasis	0.000158	0.00364	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	0.000158	0.00364	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—HCAR2—psoriasis	0.000157	0.0036	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000154	0.00354	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	0.000151	0.00347	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	0.000147	0.00338	CbGpPWpGaD
Ketobemidone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000141	0.00325	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CCL20—psoriasis	0.000139	0.00319	CbGpPWpGaD
Ketobemidone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.000137	0.00316	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—HCAR2—psoriasis	0.000137	0.00315	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	0.000135	0.00311	CbGpPWpGaD
Ketobemidone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000134	0.00307	CbGpPWpGaD
Ketobemidone—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	0.000129	0.00296	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	0.000128	0.00294	CbGpPWpGaD
Ketobemidone—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000126	0.0029	CbGpPWpGaD
Ketobemidone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000125	0.00288	CbGpPWpGaD
Ketobemidone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000124	0.00284	CbGpPWpGaD
Ketobemidone—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.00012	0.00276	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CCL20—psoriasis	0.000117	0.0027	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—CD4—psoriasis	0.000117	0.00269	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—HCAR2—psoriasis	0.000116	0.00267	CbGpPWpGaD
Ketobemidone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000108	0.00248	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—JUN—psoriasis	0.000105	0.00241	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	0.000103	0.00237	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	0.000101	0.00232	CbGpPWpGaD
Ketobemidone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.32e-05	0.00214	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—HCAR2—psoriasis	9.25e-05	0.00212	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CCL20—psoriasis	8.95e-05	0.00206	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—NDUFA5—psoriasis	8.91e-05	0.00205	CbGpPWpGaD
Ketobemidone—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	8.69e-05	0.002	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	8.57e-05	0.00197	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	8.38e-05	0.00192	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.31e-05	0.00191	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CCL20—psoriasis	8.13e-05	0.00187	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—HCAR2—psoriasis	8.11e-05	0.00186	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—TAGAP—psoriasis	8.02e-05	0.00184	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CCL20—psoriasis	7.85e-05	0.0018	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—CYP2S1—psoriasis	7.58e-05	0.00174	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	7.35e-05	0.00169	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—NDUFA5—psoriasis	7.27e-05	0.00167	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CCL20—psoriasis	7.13e-05	0.00164	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	7.07e-05	0.00162	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—TAGAP—psoriasis	7.03e-05	0.00162	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—HCAR2—psoriasis	6.85e-05	0.00157	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.78e-05	0.00156	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	6.67e-05	0.00153	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CCL20—psoriasis	6.64e-05	0.00152	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—IL6—psoriasis	6.34e-05	0.00146	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	6.21e-05	0.00143	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	6.2e-05	0.00142	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—CYP2S1—psoriasis	6.18e-05	0.00142	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CCL20—psoriasis	6.03e-05	0.00138	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—TAGAP—psoriasis	5.94e-05	0.00137	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.62e-05	0.00129	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—NDUFA5—psoriasis	5.54e-05	0.00127	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	5.38e-05	0.00124	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	5.24e-05	0.0012	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.93e-05	0.00113	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCL20—psoriasis	4.8e-05	0.0011	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—CYP2S1—psoriasis	4.71e-05	0.00108	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—NDUFA5—psoriasis	4.69e-05	0.00108	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.38e-05	0.00101	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CXCL8—psoriasis	4.28e-05	0.000983	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCL20—psoriasis	4.21e-05	0.000968	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—NDUFA5—psoriasis	4.19e-05	0.000963	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.16e-05	0.000957	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—CYP2S1—psoriasis	3.99e-05	0.000917	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.97e-05	0.000913	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.91e-05	0.000898	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—NDUFA5—psoriasis	3.82e-05	0.000878	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CXCL8—psoriasis	3.75e-05	0.000862	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—CARM1—psoriasis	3.7e-05	0.000851	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—CYP2S1—psoriasis	3.56e-05	0.000819	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.56e-05	0.000818	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCL20—psoriasis	3.56e-05	0.000818	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.46e-05	0.000795	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—CYP2S1—psoriasis	3.25e-05	0.000746	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.24e-05	0.000744	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CXCL8—psoriasis	3.17e-05	0.000729	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—CARM1—psoriasis	3.02e-05	0.000693	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.82e-05	0.000648	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—SOCS1—psoriasis	2.64e-05	0.000608	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—TYK2—psoriasis	2.52e-05	0.000579	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—NDUFA5—psoriasis	2.52e-05	0.000579	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	2.42e-05	0.000556	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—SOCS1—psoriasis	2.32e-05	0.000533	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—CARM1—psoriasis	2.3e-05	0.000529	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—CAT—psoriasis	2.28e-05	0.000523	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—TYK2—psoriasis	2.21e-05	0.000508	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CXCL8—psoriasis	2.2e-05	0.000505	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—CYP2S1—psoriasis	2.14e-05	0.000492	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	2.12e-05	0.000487	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.09e-05	0.000481	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—SOCS1—psoriasis	1.96e-05	0.00045	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—APOE—psoriasis	1.95e-05	0.000448	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—LEP—psoriasis	1.95e-05	0.000448	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—CARM1—psoriasis	1.95e-05	0.000448	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CXCL8—psoriasis	1.93e-05	0.000442	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.87e-05	0.000429	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.87e-05	0.000429	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—CAT—psoriasis	1.86e-05	0.000426	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.82e-05	0.000419	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.82e-05	0.000418	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.79e-05	0.000412	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—APOE—psoriasis	1.77e-05	0.000406	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—CARM1—psoriasis	1.74e-05	0.0004	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—LEP—psoriasis	1.71e-05	0.000393	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—APOE—psoriasis	1.71e-05	0.000393	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.7e-05	0.000391	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.63e-05	0.000374	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.63e-05	0.000374	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.59e-05	0.000366	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—CARM1—psoriasis	1.59e-05	0.000365	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—PPARG—psoriasis	1.54e-05	0.000354	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—TYK2—psoriasis	1.49e-05	0.000342	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.48e-05	0.000341	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—LEP—psoriasis	1.45e-05	0.000332	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—APOE—psoriasis	1.45e-05	0.000332	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—APOE—psoriasis	1.44e-05	0.000331	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—CAT—psoriasis	1.42e-05	0.000325	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—NFKBIA—psoriasis	1.35e-05	0.00031	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—TYK2—psoriasis	1.31e-05	0.0003	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CXCL8—psoriasis	1.3e-05	0.000298	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—PPARG—psoriasis	1.26e-05	0.000289	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—IL6—psoriasis	1.23e-05	0.000283	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—JUN—psoriasis	1.21e-05	0.000277	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—CAT—psoriasis	1.2e-05	0.000275	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—NFKB1—psoriasis	1.16e-05	0.000267	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CXCL8—psoriasis	1.14e-05	0.000261	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—TYK2—psoriasis	1.1e-05	0.000254	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—APOE—psoriasis	1.1e-05	0.000253	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—IL6—psoriasis	1.08e-05	0.000249	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—CAT—psoriasis	1.07e-05	0.000246	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—JUN—psoriasis	1.06e-05	0.000243	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—VEGFA—psoriasis	1.05e-05	0.000242	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—CARM1—psoriasis	1.05e-05	0.00024	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—STAT3—psoriasis	1.04e-05	0.00024	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—NFKB1—psoriasis	1.02e-05	0.000234	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—CAT—psoriasis	9.76e-06	0.000224	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CXCL8—psoriasis	9.61e-06	0.000221	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—PPARG—psoriasis	9.58e-06	0.00022	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—APOE—psoriasis	9.32e-06	0.000214	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—VEGFA—psoriasis	9.24e-06	0.000212	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—STAT3—psoriasis	9.15e-06	0.00021	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—IL6—psoriasis	9.14e-06	0.00021	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—JUN—psoriasis	8.94e-06	0.000205	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—NFKB1—psoriasis	8.6e-06	0.000198	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—APOE—psoriasis	8.31e-06	0.000191	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—PPARG—psoriasis	8.11e-06	0.000186	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—TP53—psoriasis	7.96e-06	0.000183	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—VEGFA—psoriasis	7.81e-06	0.000179	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—STAT3—psoriasis	7.73e-06	0.000178	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—APOE—psoriasis	7.58e-06	0.000174	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—IL6—psoriasis	7.29e-06	0.000167	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—PPARG—psoriasis	7.24e-06	0.000166	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—TP53—psoriasis	6.98e-06	0.00016	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—PPARG—psoriasis	6.6e-06	0.000152	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—CAT—psoriasis	6.44e-06	0.000148	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—IL6—psoriasis	6.39e-06	0.000147	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—TP53—psoriasis	5.9e-06	0.000136	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—IL6—psoriasis	5.4e-06	0.000124	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—APOE—psoriasis	5e-06	0.000115	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—PPARG—psoriasis	4.36e-06	0.0001	CbGpPWpGaD
